Skip to main content
Client Work

Ditch Labs secures C$ 3.25 million in seed funding

Fasken
Reading Time 1 minute read
Share
  • LinkedIn

Overview

Client

Ditch Labs

Ditch Labs, a smoking cessation platform that develops devices, digital therapeutics and AI-driven solutions, raises C$ 3.25 million in seed funding to help smokers wean themselves off nicotine.

Ditch Labs’ solution consists of a smart pulmonary nicotine inhaler, the DitchPen, that facilitates controlled delivery. The DitchPen is paired with a mobile application, the DitchApp, that provides personalized support, progress tracking, and behavioural interventions.

The seed financing was led by Amplify Capital and Boreal Ventures, with support from Symphony Health Network and Anges Québec. Investissement Québec, Meditrial, Kale Fund, and nine doctors from the United States and Canada also participated in this round.

A Fasken team composed of Guillaume Synnott and Tristan Lalumière-Roberge advised Ditch Labs in this funding.

Jurisdiction

  • Québec

Team

  • Guillaume Synnott, Partner, Montréal, QC, +1 514 397 4325, gsynnott@fasken.com
  • Tristan Lalumière-Roberge, Associate, Montréal, QC, +1 514 397 5216, tlalumiere@fasken.com